News & Events about I Mab.
Thinking about buying stock in Dermata Therapeutics, Silo Pharma, IQIYI, First Wave BioPharma, or I-Mab? Thinking about buying stock in Dermata Therapeutics, Silo Pharma, IQIYI, First Wave BioPharma, or I-Mab? PR Newswire NEW YORK, Dec. 30, 2022 NEW YORK, Dec. 30, 2022 /PRNewswire...
TheStreet.com - Investing
1month ago
Here are the most undervalued stocks tracked by Morningstar, as measured by its fair-value estimates.Here are the most undervalued stocks tracked by Morningstar, as measured by its fair-value estimates.With the S&P 500 having dropped 19% year to date, you might be thinking now is the time to pick up...
I-Mab Announces Poster Presentations of CD47 Antibody Lemzoparlimab and CD73 Antibody Uliledlimab at SITC 2022 I-Mab Announces Poster Presentations of CD47 Antibody Lemzoparlimab and CD73 Antibody Uliledlimab at SITC 2022 PR Newswire GAITHERSBURG, MD. and SHANGHAI, China, Oct. 5, 2022 GAITHERSBURG...
I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022 I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic...
Business Wire
4 months ago
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of I-Mab (I-Mab or the Company) (NASDAQ: IMAB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading...